

SUBSCRIBE TO OUR FREE NEWSLETTER
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
5
#000000
#FFFFFF
To donate by check, phone, or other method, see our More Ways to Give page.


Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.

Demonstrator protests on June 12, 2021, in Hayle, Cornwall as the U.K. Prime Minister, Boris Johnson, hosts leaders from the USA, Japan, Germany, France, Italy and Canada at the G7 Summit in Carbis Bay. (Photo: Jeff J Mitchell/Getty Images)
Public Citizen recently uncovered "an agreement that the European Commission reached with Pfizer and BioNTech last November to purchase 100 million doses of the companies" mRNA vaccine, which was developed with the support of government funding and U.S. taxpayer-financed technology.
In the 104-page contract, Public Citizen found a list of manufacturing specifications for the Pfizer-BioNTech vaccine, including particular composition and strength, identity, and purity requirements followed throughout the production process.
Public Citizen's website says, "This info can help mRNA vaccine scientists by illustrating the kinds of requirements they need to meet critical quality standards." Such agreements have a widely recognized ability to enhance the parties' market power, but less attention is paid to the effects on the direction of scientific research.
Public Citizen discovered is that safe and effective vaccines are more than individual accomplishments. Not only is the basic research publically financed, the process of converting it to a product safe for human consumption is dependent on a complex manufacturing infrastructure of quality control and trained personnel to operate that infrastructure.
Recognizing that vaccines are social products, both basic formula and technical specifications, argues not only for suspending or revoking patent protection but equally important sharing technological know how. Currently much scientific research is conducted behind a screen of corporate control, out of concern that sharing may weaken any patent claim.
Patent monopolies and hoarded production techniques are supposed to foster incentives to find and develop new miracle cures. This view has been widely critiqued, in part by pointing to the role of government subsidy. But there is another downside to the conventional model. That model's emphasis on secrecy in preparation for patent claims and patent litigation impedes communication among scientists and renders their work far short of science's transparency standard.
"Sharing information can help ramp up Covid vaccine production. Sharing information can also advance mRNA science by allowing scientists to quickly learn from each other's work," Public Citizen said. "Indeed, the development of safe and effective mRNA vaccines builds on decades of scientific discoveries across many different institutions. Secrecy makes us less safe against this virus--and future pandemic threats."
Current drug research, development, and marketing priorities are based on an effort to limit competition at every step of the journey. "Big Pharma's business model--receive billions in public investments, charge exorbitant prices for lifesaving medicines, pay little tax--is gold dust for wealthy investors and corporate executives but devastating for global public health," said Robbie Silverman, Oxfam America's private sector engagement manager, in a statement.
"Instead of partnering with governments and other qualified manufacturers to make sure that we have enough vaccine doses for everyone, these pharmaceutical companies prioritize their own profits by enforcing their monopolies and selling to the highest bidder," he added. "Enough is enough--we must start putting people before profits."
Dear Common Dreams reader, It’s been nearly 30 years since I co-founded Common Dreams with my late wife, Lina Newhouser. We had the radical notion that journalism should serve the public good, not corporate profits. It was clear to us from the outset what it would take to build such a project. No paid advertisements. No corporate sponsors. No millionaire publisher telling us what to think or do. Many people said we wouldn't last a year, but we proved those doubters wrong. Together with a tremendous team of journalists and dedicated staff, we built an independent media outlet free from the constraints of profits and corporate control. Our mission has always been simple: To inform. To inspire. To ignite change for the common good. Building Common Dreams was not easy. Our survival was never guaranteed. When you take on the most powerful forces—Wall Street greed, fossil fuel industry destruction, Big Tech lobbyists, and uber-rich oligarchs who have spent billions upon billions rigging the economy and democracy in their favor—the only bulwark you have is supporters who believe in your work. But here’s the urgent message from me today. It's never been this bad out there. And it's never been this hard to keep us going. At the very moment Common Dreams is most needed, the threats we face are intensifying. We need your support now more than ever. We don't accept corporate advertising and never will. We don't have a paywall because we don't think people should be blocked from critical news based on their ability to pay. Everything we do is funded by the donations of readers like you. When everyone does the little they can afford, we are strong. But if that support retreats or dries up, so do we. Will you donate now to make sure Common Dreams not only survives but thrives? —Craig Brown, Co-founder |
Public Citizen recently uncovered "an agreement that the European Commission reached with Pfizer and BioNTech last November to purchase 100 million doses of the companies" mRNA vaccine, which was developed with the support of government funding and U.S. taxpayer-financed technology.
In the 104-page contract, Public Citizen found a list of manufacturing specifications for the Pfizer-BioNTech vaccine, including particular composition and strength, identity, and purity requirements followed throughout the production process.
Public Citizen's website says, "This info can help mRNA vaccine scientists by illustrating the kinds of requirements they need to meet critical quality standards." Such agreements have a widely recognized ability to enhance the parties' market power, but less attention is paid to the effects on the direction of scientific research.
Public Citizen discovered is that safe and effective vaccines are more than individual accomplishments. Not only is the basic research publically financed, the process of converting it to a product safe for human consumption is dependent on a complex manufacturing infrastructure of quality control and trained personnel to operate that infrastructure.
Recognizing that vaccines are social products, both basic formula and technical specifications, argues not only for suspending or revoking patent protection but equally important sharing technological know how. Currently much scientific research is conducted behind a screen of corporate control, out of concern that sharing may weaken any patent claim.
Patent monopolies and hoarded production techniques are supposed to foster incentives to find and develop new miracle cures. This view has been widely critiqued, in part by pointing to the role of government subsidy. But there is another downside to the conventional model. That model's emphasis on secrecy in preparation for patent claims and patent litigation impedes communication among scientists and renders their work far short of science's transparency standard.
"Sharing information can help ramp up Covid vaccine production. Sharing information can also advance mRNA science by allowing scientists to quickly learn from each other's work," Public Citizen said. "Indeed, the development of safe and effective mRNA vaccines builds on decades of scientific discoveries across many different institutions. Secrecy makes us less safe against this virus--and future pandemic threats."
Current drug research, development, and marketing priorities are based on an effort to limit competition at every step of the journey. "Big Pharma's business model--receive billions in public investments, charge exorbitant prices for lifesaving medicines, pay little tax--is gold dust for wealthy investors and corporate executives but devastating for global public health," said Robbie Silverman, Oxfam America's private sector engagement manager, in a statement.
"Instead of partnering with governments and other qualified manufacturers to make sure that we have enough vaccine doses for everyone, these pharmaceutical companies prioritize their own profits by enforcing their monopolies and selling to the highest bidder," he added. "Enough is enough--we must start putting people before profits."
Public Citizen recently uncovered "an agreement that the European Commission reached with Pfizer and BioNTech last November to purchase 100 million doses of the companies" mRNA vaccine, which was developed with the support of government funding and U.S. taxpayer-financed technology.
In the 104-page contract, Public Citizen found a list of manufacturing specifications for the Pfizer-BioNTech vaccine, including particular composition and strength, identity, and purity requirements followed throughout the production process.
Public Citizen's website says, "This info can help mRNA vaccine scientists by illustrating the kinds of requirements they need to meet critical quality standards." Such agreements have a widely recognized ability to enhance the parties' market power, but less attention is paid to the effects on the direction of scientific research.
Public Citizen discovered is that safe and effective vaccines are more than individual accomplishments. Not only is the basic research publically financed, the process of converting it to a product safe for human consumption is dependent on a complex manufacturing infrastructure of quality control and trained personnel to operate that infrastructure.
Recognizing that vaccines are social products, both basic formula and technical specifications, argues not only for suspending or revoking patent protection but equally important sharing technological know how. Currently much scientific research is conducted behind a screen of corporate control, out of concern that sharing may weaken any patent claim.
Patent monopolies and hoarded production techniques are supposed to foster incentives to find and develop new miracle cures. This view has been widely critiqued, in part by pointing to the role of government subsidy. But there is another downside to the conventional model. That model's emphasis on secrecy in preparation for patent claims and patent litigation impedes communication among scientists and renders their work far short of science's transparency standard.
"Sharing information can help ramp up Covid vaccine production. Sharing information can also advance mRNA science by allowing scientists to quickly learn from each other's work," Public Citizen said. "Indeed, the development of safe and effective mRNA vaccines builds on decades of scientific discoveries across many different institutions. Secrecy makes us less safe against this virus--and future pandemic threats."
Current drug research, development, and marketing priorities are based on an effort to limit competition at every step of the journey. "Big Pharma's business model--receive billions in public investments, charge exorbitant prices for lifesaving medicines, pay little tax--is gold dust for wealthy investors and corporate executives but devastating for global public health," said Robbie Silverman, Oxfam America's private sector engagement manager, in a statement.
"Instead of partnering with governments and other qualified manufacturers to make sure that we have enough vaccine doses for everyone, these pharmaceutical companies prioritize their own profits by enforcing their monopolies and selling to the highest bidder," he added. "Enough is enough--we must start putting people before profits."